Early yet on Side Effects, wait and see what happens.
SOURCE: https://www.nytimes.com/2021/06/14/health/covid-vaccine-novavax.html
Despite these impressive results, the vaccine’s future in the United States is uncertain and it might be needed more in other countries. Novavax says it may not seek emergency authorization from the Food and Drug Administration until the end of September. And with a plentiful supply of three other authorized vaccines, it’s possible that the agency may tell Novavax to apply instead for a full license — a process that could require several extra months.
The company’s chief executive, Stanley Erck, acknowledged in an interview that Novavax would probably win its first authorization elsewhere. The company is also applying in Britain, the European Union, India and South Korea.
“I think the good news is that the data are so compelling that it gives everybody an incentive to pay attention to our filings,” Mr. Erck said.
By the time Novavax gets the green light from the U.S. government, it may be too late to contribute to the country’s first wave of vaccinations. But many vaccine experts expect that, with waning immunity and emerging variants, the country will need booster shots at some point. And the protein-based technology used in the Novavax vaccine may do a particularly good job at amplifying protection, even if people have previously been vaccinated with a different formulation.